Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50-Day Moving Average of $2.74

Minerva Neurosciences, Inc. (NASDAQ:NERVGet Free Report)’s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.74 and traded as high as $3.16. Minerva Neurosciences shares last traded at $3.15, with a volume of 8,434 shares trading hands.

Analysts Set New Price Targets

NERV has been the subject of several research reports. HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday, May 2nd. StockNews.com assumed coverage on Minerva Neurosciences in a research report on Thursday. They issued a “sell” rating for the company.

Read Our Latest Stock Report on Minerva Neurosciences

Minerva Neurosciences Price Performance

The business has a 50-day moving average of $2.74 and a 200-day moving average of $4.67. The company has a market capitalization of $22.02 million, a P/E ratio of -0.70 and a beta of 0.13.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. Sell-side analysts predict that Minerva Neurosciences, Inc. will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Read More

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.